Cell Therapies for Life-Threatening Diseases
LyGenesis (lygenesis.com) scores 68 out of 100 on Brand Analyzer, placing it in the Developing tier among Healthcare brands, in the 17th percentile of 16240 Healthcare brands.
LyGenesis is a clinical-stage cell therapy company focused on treating life-threatening organ diseases, including end-stage liver disease, end-stage renal disease, and Type 1 diabetes. Its core technology transforms a patient's own lymph nodes into bioreactors that grow functioning ectopic organs, potentially allowing a single donated organ to treat multiple patients through a minimally invasive outpatient procedure. The company positions itself as addressing major unmet needs in organ transplantation economics, targeting patients, the medical community, and investors interested in regenerative medicine.
| Brand Name | LyGenesis |
|---|---|
| Domain | lygenesis.com |
| Industry | Healthcare |
| Main Competitors | Miromatrix Medical (72/100), United Therapeutics (77/100), eGenesis, Vertex Pharmaceuticals (88/100), Organovo (78/100), Sana Biotechnology |
Moz Domain Authority 39/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Cell therapies for life-threatening diseases" (Meta description: 5 words. OG description present but brief) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:description, Twitter cards. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Vue.
Social footprint: verified profiles on LinkedIn, X (Twitter), Facebook, Instagram; no detected presence on YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is LyGenesis?", Claude could identify the brand as of October 2026. LyGenesis is a clinical-stage biotechnology company developing a regenerative medicine platform that uses a patient's own lymph nodes as 'bioreactors' to grow functional ectopic organs, most notably liver tissue, to treat organ failure. Their lead program injects hepatocytes into Best known for Using lymph nodes as bioreactors to grow ectopic liver tissue to treat end-stage liver disease.
When asked "Best brands similar to LyGenesis?", Claude would recommend LyGenesis as of October 2026. It's a notable and fairly unique name in regenerative medicine/organ engineering, so it's worth mentioning if someone asks about innovative approaches to organ failure or regenerative therapies.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
LyGenesis's main competitors in Healthcare: Miromatrix Medical (72/100), United Therapeutics (77/100), Vertex Pharmaceuticals (88/100), Organovo (78/100).
Sources: Brand Analyzer scan
LyGenesis has low AI-search visibility, scoring 11/100 on Brand Analyzer's AI visibility composite (visibility 0, trust 15, recommendation 27). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: LyGenesis official site
LyGenesis offers a cell therapy platform that uses a patient's own lymph nodes as bioreactors to grow functioning ectopic organs. This is intended to treat life-threatening organ diseases, including end-stage liver disease, end-stage renal disease, and Type 1 diabetes, through a minimally invasive outpatient procedure.
Sources: LyGenesis official site
LyGenesis scores 27/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: LyGenesis official site
LyGenesis is a clinical-stage cell therapy company developing treatments for life-threatening organ diseases. It focuses on conditions such as end-stage liver disease, end-stage renal disease, and Type 1 diabetes, using a proprietary approach that leverages a patient's own lymph nodes as bioreactors to grow functioning ectopic organs.
Sources: LyGenesis official site
LyGenesis develops cell therapies that transform a patient's own lymph nodes into bioreactors capable of growing functioning ectopic organs. This approach is designed to allow a single donated organ to potentially treat dozens of patients through a minimally invasive outpatient procedure, rather than requiring full organ transplantation for each patient.
Sources: LyGenesis official site
LyGenesis can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: LyGenesis official site
LyGenesis is known for its novel approach to organ regeneration, using a patient's own lymph nodes as bioreactors to grow functioning ectopic organs. This technology aims to multiply the therapeutic reach of a single donated organ, addressing shortages in organ transplantation for conditions like end-stage liver disease, end-stage renal disease, and Type 1 diabetes.
Sources: LyGenesis official site
LyGenesis' therapies are intended for patients suffering from life-threatening organ diseases, such as end-stage liver disease, end-stage renal disease, and Type 1 diabetes. Additionally, the medical community and investors interested in regenerative cell therapies engage with the company's research and clinical development work.
Sources: LyGenesis official site
LyGenesis scores 11/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
LyGenesis has a weak AI-visibility profile at 11/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (27/100) and its weakest is visibility (0/100). It benefits from open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, no strong Wikidata entry and a low Moz Domain Authority of 39/100. In a live check, Claude could already identify LyGenesis from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to LyGenesis: Longevity Advice (68/100), リニカル (Linical) (68/100), Madaket Health (68/100), MADO Healthcare (68/100).
A step up - brands to learn from: Zentralwohlfahrtsstelle der Juden in Deutschland e.V. (71/100), ZT Corporate (71/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.